PART I Item 1. B usiness. Overview We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. We are generating a portfolio of differentiated programs that are designed to harness the bodys natural RNA editing process to effect a precise yet transient change to a single nucleoside (adenosine to an inosine edit). By editing RNA instead of DNA, we ...
Q2 FY2026 — expected 2026-08-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104156 | EDGAR | 102K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-040759 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036396 | EDGAR | — |
| 2023-03-10 | 2022-12-31 | 0000950170-23-007140 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0000950170-22-003655 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001564590-21-016117 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001564590-20-012977 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277572 | EDGAR | 62K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-106912 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065800 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125362 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096189 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059493 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058171 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041300 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0000950170-23-021755 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023231 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016072 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007423 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001193125-26-104135 | EDGAR | 3K words |
| 2026-03-09 | 0001193125-26-097575 | EDGAR | — |
| 2026-01-27 | 0001193125-26-023436 | EDGAR | — |
| 2026-01-15 | 0001193125-26-014087 | EDGAR | — |
| 2025-12-18 | 0001193125-25-324795 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277556 | EDGAR | — |
| 2025-10-08 | 0001193125-25-234001 | EDGAR | — |
| 2025-08-12 | 0000950170-25-106910 | EDGAR | — |
| 2025-06-11 | 0000950170-25-084846 | EDGAR | — |
| 2025-05-07 | 0000950170-25-065786 | EDGAR | — |
132 total filings indexed. 103 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001703647 |
| Ticker | KRRO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.korrobio.com |
| Listed | 2023-11-06 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report